​
​

Nuvalent (NUVL) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

NUVL Stock Forecast

Nuvalent stock forecast is as follows: an average price target of $111.57 (represents a 17.53% upside from NUVL’s last price of $94.93) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.

NUVL Price Target

The average price target for Nuvalent (NUVL) is $111.57 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $135.00 to $97.00. This represents a potential 17.53% upside from NUVL's last price of $94.93.

NUVL Analyst Ratings

Buy

According to 10 Wall Street analysts, Nuvalent's rating consensus is 'Buy'. The analyst rating breakdown for NUVL stock is 0 'Strong Buy' (0.00%), 9 'Buy' (90.00%), 1 'Hold' (10.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Nuvalent Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 13, 2024Etzer DaroutBMO Capital--91.46%41.16%
Oct 24, 2024David DaiUBS--6.71%5.34%
Sep 16, 2024Kelsey GoodwinGuggenheim---4.76%10.61%
Sep 16, 2024Bradley CaninoStifel Nicolaus--54.37%42.21%
Sep 16, 2024Christopher RaymondRaymond James--14.35%5.34%
Jul 10, 2024Bradley CaninoStifel Nicolaus--56.19%21.14%
Apr 17, 2024Roger SongJefferies--49.81%2.18%
Apr 01, 2024Christopher LiuLeerink Partners--46.49%15.87%
Row per page
Go to

The latest Nuvalent stock forecast, released on Nov 13, 2024 by Etzer Darout from BMO Capital, set a price target of $134.00, which represents a 91.46% increase from the stock price at the time of the forecast ($69.99), and a 41.16% increase from NUVL last price ($94.93).

Nuvalent Price Target by Period

1M3M12M
# Anlaysts158
Avg Price Target$134.00$114.80$112.00
Last Closing Price$94.93$94.93$94.93
Upside/Downside41.16%20.93%17.98%

In the current month, the average price target of Nuvalent stock is $134.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 41.16% increase as opposed to Nuvalent's last price of $94.93. This month's average price target is up 16.72% compared to last quarter, and up 19.64% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 24, 2024UBSNeutralInitialise
Sep 16, 2024GuggenheimBuyBuyHold
Sep 16, 2024Cowen & Co.BuyBuyHold
Sep 16, 2024WedbushOutperformOutperformHold
Sep 16, 2024Piper SandlerOverweightOverweightHold
Sep 16, 2024BMO CapitalOutperformOutperformHold
Aug 29, 2024BarclaysOverweightInitialise
Apr 17, 2024JefferiesBuyInitialise
Apr 01, 2024Leerink PartnersOutperformUpgrade
Aug 08, 2023SVB LeerinkOutperformInitialise
Row per page
Go to

Nuvalent's last stock rating was published by UBS on Oct 24, 2024. The company Initialise its NUVL rating from "null" to "Neutral".

Nuvalent Financial Forecast

Nuvalent Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast$10.71M$666.67K-----
High Forecast$10.71M$666.67K-----
Low Forecast$10.71M$666.67K-----
# Analysts11-----
Surprise %-------

Nuvalent's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NUVL's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Nuvalent EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts11-----
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict NUVL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Nuvalent's previous annual EBITDA (undefined) of $NaN.

Nuvalent Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts11-----
Net Income-------
Avg Forecast$-74.99M$-77.65M$-72.65M$-67.86M$-70.22M$-61.35M$-49.30M
High Forecast$-74.99M$-77.65M$-72.65M$-59.55M$-58.40M$-61.35M$-49.30M
Low Forecast$-74.99M$-77.65M$-72.65M$-75.48M$-89.00M$-61.35M$-49.30M
Surprise %-------

Nuvalent's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NUVL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Nuvalent SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts11-----
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Nuvalent's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NUVL last annual SG&A of $NaN (undefined).

Nuvalent EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts11-----
EPS-------
Avg Forecast$-1.14$-1.18$-1.11$-1.03$-1.07$-0.93$-0.76
High Forecast$-1.14$-1.18$-1.11$-0.91$-0.89$-0.93$-0.76
Low Forecast$-1.14$-1.18$-1.11$-1.15$-1.36$-0.93$-0.76
Surprise %-------

According to undefined Wall Street analysts, Nuvalent's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NUVL previous annual EPS of $NaN (undefined).

Nuvalent Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
VTYXVentyx Biosciences--1730.27%Buy
GPCRStructure Therapeutics--176.56%Buy
CGEMCullinan Oncology--151.20%Buy
VRDNViridian Therapeutics--87.72%Buy
KNSAKiniksa Pharmaceuticals--70.72%Buy
REPLReplimune Group--62.09%Buy
ASNDAscendis Pharma--46.53%Buy
PCVXVaxcyte--40.05%Buy
DICEDICE Therapeutics--26.18%Buy
TVTXTravere Therapeutics--19.18%Buy
NUVLNuvalent--17.53%Buy
UTHRUnited Therapeutics---3.94%Buy
ACLXArcellx---8.23%Buy
CERECerevel Therapeutics---25.49%Buy

NUVL Forecast FAQ

Is Nuvalent a good buy?

Yes, according to 10 Wall Street analysts, Nuvalent (NUVL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 90.00% of NUVL's total ratings.

What is NUVL's price target?

Nuvalent (NUVL) average price target is $111.57 with a range of $97 to $135, implying a 17.53% from its last price of $94.93. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Nuvalent stock go up soon?

According to Wall Street analysts' prediction for NUVL stock, the company can go up by 17.53% (from the last price of $94.93 to the average price target of $111.57), up by 42.21% based on the highest stock price target, and up by 2.18% based on the lowest stock price target.

Can Nuvalent stock reach $140?

NUVL's average twelve months analyst stock price target of $111.57 does not support the claim that Nuvalent can reach $140 in the near future.

What is Nuvalent's current price target trend?

1 Wall Street analyst forecast a $134 price target for Nuvalent (NUVL) this month, up 41.16% from its last price of $94.93. Compared to the last 3 and 12 months, the average price target increased by 20.93% and increased by 17.98%, respectively.

What are Nuvalent's analysts' financial forecasts?

Nuvalent's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-181M (high $-169M, low $-200M), average SG&A $0 (high $0, low $0), and average EPS is $-2.767 (high $-2.587, low $-3.052). NUVL's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $11.38M (high $11.38M, low $11.38M), average EBITDA is $0 (high $0, low $0), average net income is $-293M (high $-285M, low $-301M), average SG&A $0 (high $0, low $0), and average EPS is $-4.463 (high $-4.337, low $-4.579).